Phase II results of the first clinical trial of a tau aggregation inhibitor for Alzheimer's disease were published last month in the Journal of Alzheimer's Disease, with Singapore-based TauRx Pharmaceuticals saying it was an important milestone as it moves to report top line results from a Phase III study in 2016.
Researchers have discovered that a skin sample taken from behind the ear of patients with either Alzheimer's or Parkinson's disease had levels of the protein tau 7 times higher than those without the condition. Those with Parkinson's showed levels of alpha-synuclein protein that were 8 times higher than those in the control group.
Akili Interactive Labs has partnered with the nonprofit Autism Speaks to conduct a clinical trial of its cognitive assessment and personalized treatment video game.
Scientists at some of the most prestigious research institutions in the U.K. and Sweden say they've found a molecule that could disarm the toxic clusters of amyloid beta that are believed to trigger Alzheimer's, offering a new approach to treating the disease.
Japan's Sosei Group said it has acquired all of Heptares Therapeutics, a U.K.-based biotech focused on Alzheimer's disease and diabetes.
Alzheimer's Research UK is setting up a trio of discovery units in the Golden Triangle with plans to recruit dozens of investigators to advance new work on therapeutics for the memory-robbing disease.
The former head of Johnson & Johnson's initiative to develop stratified drugs for Alzheimer's disease is trying to crowdfund the development of computer simulations of brain disorders. Magali Haas is seeking $299,900 for the project, which builds on a multiple sclerosis prediction model created by her nonprofit, Orion Bionetworks.
Neurogeneticists at the University of Southern California say that they were able to use immune cells to clear away amyloid beta, the toxic protein that may be the cause of Alzheimer's.
The steady sequence of failed clinical studies in Alzheimer's has underscored just how much researchers in the field have to learn about the science of forming and retaining memories.
Building on research into the way in which glial cells called astrocytes store memories, a group of investigators at the Gladstone Institutes has zeroed in on a particular target--A2A adenosine receptors--that could play a role in preventing one of the most devastating symptoms of Alzheimer's.